Aug 6, 2025 07:59AM Q32 Bio (QTTB) Misses Q2 EPS by 78c

Jun 25, 2025 06:59AM Q32 Bio (QTTB) Appoints Adrien Sipos as Interim Chief Medical Officer

May 8, 2025 04:46PM Q32 Bio (QTTB) Misses Q1 EPS by 90c

Apr 30, 2025 07:00AM Q32 Bio (QTTB) Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Apr 16, 2025 07:02AM Q32 Bio (QTTB) Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Mar 20, 2025 04:24PM Oppenheimer Reiterates Outperform Rating on Q32 Bio Inc. (QTTB), PT $20

Mar 11, 2025 04:53PM Q32 Bio (QTTB) Misses Q4 EPS by 116c

Feb 11, 2025 07:26AM BMO Capital Downgrades Q32 Bio Inc. (QTTB) to Market Perform

Feb 11, 2025 03:09AM Piper Sandler Downgrades Q32 Bio Inc. (QTTB) to Neutral

Feb 10, 2025 04:05PM Q32 Bio (QTTB) Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Dec 12, 2024 09:04AM Q32 Bio Inc. (QTTB) PT Slashed to $22 at BMO Capital; '(Disappointing) Results Not a Surprise to Us'

Dec 11, 2024 07:25AM Q32 Bio Inc. (QTTB) PT Slashed to $20 at Piper Sandler Following 'Messy' P2a Readouts

Dec 11, 2024 06:37AM Q32 Bio Inc. (QTTB) PT Lowered to $20 at Oppenheimer

Dec 11, 2024 06:20AM Leerink Partners Downgrades Q32 Bio Inc. (QTTB) to Market Perform

Dec 11, 2024 05:41AM Wells Fargo Downgrades Q32 Bio Inc. (QTTB) to Equal Weight

Dec 11, 2024 02:52AM Raymond James Downgrades Q32 Bio Inc. (QTTB) to Outperform

Dec 10, 2024 04:50PM After-hours movers: GM, Stitch Fix, Dave & Buster's, GME and more

Dec 10, 2024 04:21PM Q32 Bio (QTTB) SIGNAL-AD trial did not achieve its primary endpoint, SIGNAL-AA demonstrated encouraging clinical activity

Dec 5, 2024 04:10PM BMO Capital Starts Q32 Bio Inc. (QTTB) at Outperform

Oct 16, 2024 06:22AM Oppenheimer Reiterates Outperform Rating on Q32 Bio Inc. (QTTB)

Sep 11, 2024 05:56AM Wells Fargo Starts Q32 Bio Inc. (QTTB) at Overweight

Aug 19, 2024 05:51AM Piper Sandler Reiterates Overweight Rating on Q32 Bio Inc. (QTTB)

Aug 8, 2024 09:22AM Q32 Bio (QTTB) Misses Q2 EPS by 142c

Jul 9, 2024 06:59AM Q32 Bio (QTTB) Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Jul 1, 2024 06:59AM Q32 Bio (QTTB) to Join Russell 3000